EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Nerolidol inhibited U-251 human glioblastoma cell proliferation and triggered apoptosis via the upregulation of the p38 MAPK signaling pathway

Zhijin Lu, Tao Tang, Juan Huang, Yongqiang Shi

Advances in Clinical and Experimental Medicine · 2023

DOI: 10.17219/acem/170184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Zhijin Lu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Trauma Surgery Emergency Center, Ganzhou People's Hospital, China. Hauptthemen laut MEDLINE: Glioblastoma, Apoptosis, Sesquiterpenes, Cell Proliferation. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glioblastoma multiforme (GBM) is a lethal brain tumor with high mortality and morbidity. Nerolidol (NRD) is a sesquiterpene alcohol sequestered from the essential oils of aromatic florae with potent antioxidant, antiviral, anticancer, cardioprotective, and neuroprotective activity. OBJECTIVES: The aim of the study was to investigate the underlying cell-cycle mechanisms of NRD-mediated antiproliferative and apoptosis activities in GBM using human U-251 cells. MATERIAL AND METHODS: The current research investigated the antiproliferative and apoptotic activities of NRD on U-251 cells. The effects of NRD were measured using a Cell Counting Kit-8 (CCK-8) assay, 4',6-diamidino-2-phenylindole (DAPI) staining, messenger ribonucleic acid (mRNA) level assessment, and western blot assay. RESULTS: Nerolidol decreased U-251 viability in a dose-dependent manner, as well as induced apoptotic activity, reduced B-cell lymphoma-2 (BCL-2) levels, and increased mRNA expression of BCL-2-associated X (Bax), caspase-3 and caspase-9. The attenuation of the cyclin-D1, cyclin-dependent kinase 4 (CDK4) and CDK6 mRNA expression confirmed cell cycle regulation. Western blot analysis of CDK1 indicated reductions in cyclin-B1 and p21. Furthermore, NRD prompted apoptosis through p38 amelioration and increased phosphorylated extracellular signal-related kinase 1 (p-ERK1) and phosphorylated c-Jun N-terminal protein kinase 1 (p-JNK1) levels. CONCLUSIONS: Nerolidol inhibited GBM cell viability and induced apoptosis through the regulation of cell-cycle proteins via p38 mitogen-activated protein kinase (MAPK) signaling pathways. Thus, NRD could be developed as a potential natural therapeutic agent for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaApoptosisSesquiterpenesCell Proliferationp38 Mitogen-Activated Protein KinasesHumansCell Line, TumorUp-RegulationMAP Kinase Signaling SystemBrain NeoplasmsCell Survival

Stichwörter der Autor:innen

U-251 cellsapoptosisglioblastomanerolidolp38 MAPK

Substanzen

Sesquiterpenesp38 Mitogen-Activated Protein Kinasesnerolidol

Autor:innen und Institutionen

  • Trauma Surgery Emergency Center, Ganzhou People's Hospital, China.
  • Physical Examination Center, Ganzhou People's Hospital, China.
  • Surgical Intensive Care Unit, Xi'an Children's Hospital, China.
  • Department of Neurosurgery, Xi'an Children's Hospital, China.

Zitieren

APA

Lu, Z., Tang, T., Huang, J., & Shi, Y. (2023). Nerolidol inhibited U-251 human glioblastoma cell proliferation and triggered apoptosis via the upregulation of the p38 MAPK signaling pathway. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/170184

Vancouver

Lu Z, Tang T, Huang J, Shi Y. Nerolidol inhibited U-251 human glioblastoma cell proliferation and triggered apoptosis via the upregulation of the p38 MAPK signaling pathway. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/170184

BibTeX
@article{Lu2023,
  author = {Lu, Zhijin and Tang, Tao and Huang, Juan and Shi, Yongqiang},
  title = {Nerolidol inhibited U-251 human glioblastoma cell proliferation and triggered apoptosis via the upregulation of the p38 MAPK signaling pathway},
  journal = {Advances in Clinical and Experimental Medicine},
  year = {2023},
  doi = {10.17219/acem/170184}
}
Kostenlos starten →